Alamar Biosciences (ALMR) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.95B and a free-cash-flow yield of -3.2%. Over the most recent reported fiscal year, revenue grew 195.2%. Nama's AI scorecard rates it Sell, 4.2 out of 10.
AI scorecard
Sell · 4.2/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-29.2%
How far the last close sits under the highest price of the past five years.
Market cap
$1.95B
Trailing P/E
—
Price / book
6.2
Price / sales
19.3
FCF yield
-3.2%
Dividend yield
—
Gross margin
55.6%
Operating margin
-50.0%
Net margin
-58.1%
Revenue growth (YoY)
+195.2%
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Medical Devices
ALMR earnings
Next report: Feb 18, 2027 (Q4 2026, EPS estimate -$0.26).
Beat the EPS estimate in 1 of 2 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 3, 2026
-$0.19
-$0.19
+0.0%
$33.55M
Q2 2026
Aug 10, 2026
-$0.20
-$0.32
+37.5%
$29.43M
ALMR analyst price target
Median target $35.00 from 5 analysts, ranging $32.00 – $45.00.
Nama's AI scorecard currently rates Alamar Biosciences Sell (4.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ALMR report earnings?
Alamar Biosciences's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.26.
What is the ALMR price target?
The median analyst price target from 5 analysts is $35.00, with a range of $32.00 – $45.00.
Is ALMR Shariah compliant?
Nama's AAOIFI-style screen reads Alamar Biosciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.